Aptamer Group plc




Advanced Medical Equipment & Technology

Market Closed - London S.E. 11:35:05 2024-05-17 am EDT 5-day change 1st Jan Change
0.725 GBX 0.00% Intraday chart for Aptamer Group plc -0.68% -36.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aptamer says sales pipeline "strong" as reports strategic headway AN
EARNINGS AND TRADING: Zenova's Kitemark award; Carnival's eyes savings AN
Aptamer inks new Optimer+ transplant rejection therapy partnership AN
Aptamer Group, Kairos Biotech Team Up to Improve Transplant Success MT
Aptamer Group Files Patent Application for Optimer Binders MT
Aptamer submits patent application for Optimer binders AN
EARNINGS AND TRADING: Arbuthnot ups payout as profit more than doubles AN
Aptamer Group plc Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Zentek Says Potential COVID-19 Drug Shows 'Promising' Safety Profile in Preclinical Trial MT
Transcript : Aptamer Group plc - Special Call
Transcript : Aptamer Group plc - Pre Recorded Special Call
Aptamer shares jump on successful Unilever contract progression AN
Aptamer Group, Unilever Prepare to Patent Optimers Developed Under Partnership MT
Aptamer says new Optimer+ delivers improved results AN
Aptamer Group plc Announces R&D Progress on New Optimer®? + Platform CI
Aptamer and Neuro-Bio begin Alzheimer's test development second phase AN
Aptamer Group, Neuro-Bio Enter Second Phase of Partnership for Alzheimer's Flow Test Development MT
Aptamer shares plunge as half-year revenue to fall by 70% AN
Aptamer Group plc Provides Revenue Guidance for the First Half of the Fiscal Year 2024 CI
Zentek Announces "Positive" Therapeutic Results Achieved by Triera Biosciences for C19HBA MT
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research MT
Ribomic Enters Into Drug Research Collaboration with Ajinomoto MT
Aptamer inks deal for Optimer discovery with biotech firm AN
Aptamer Group Signs Optimer Discovery Deal With Genetic Medicines Company MT
Aptamer Group plc Announces Material Agreement with Genetic Medicines Company CI
Chart Aptamer Group plc
More charts
Aptamer Group plc is a United Kingdom-based company that develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers next-generation aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA). Its Optimer platform supports a diverse portfolio of partners and technologies.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. APTA Stock
  4. News Aptamer Group plc
  5. Aptamer Group Files Patent Application for Optimer Binders
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.